Risk assessment in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study.
Qian WangJunyan QianMeng Tao LiXiao ZhangWei WeiXiaoxia ZuoPing ZhuShuang YeWei ZhangYi ZhengWufang QiYang LiZhuoli ZhangFeng DingJieruo GuYi LiuCan HuangJiu-Liang ZhaoYongtai LiuZhuang TianYanhong WangMiaojia ZhangXiao-Feng ZengPublished in: Therapeutic advances in chronic disease (2022)
The risk assessment has a significant prognostic value at both the baseline and first follow-up assessment of SLE-associated PAH. A noninvasive risk assessment can also be useful when RHC is not available during follow-up. Baseline serositis may be a predictor of good treatment response in patients with SLE-associated PAH.